BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB. Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache 2019;59:1286-99. [PMID: 31407321 DOI: 10.1111/head.13613] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 23.7] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen JL, Munshi K, Peasah SK, Swart ECS, Kohli M, Henderson R, Good CB. Trends in utilization and costs of migraine medications, 2017–2020. J Headache Pain 2022;23. [DOI: 10.1186/s10194-022-01476-y] [Reference Citation Analysis]
2 Vincent M, Viktrup L, Nicholson RA, Ossipov MH, Vargas BB. The not so hidden impact of interictal burden in migraine: A narrative review. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1032103] [Reference Citation Analysis]
3 Pozo-Rosich P, Dodick DW, Ettrup A, Hirman J, Cady R. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies. BMC Neurol 2022;22:394. [PMID: 36284281 DOI: 10.1186/s12883-022-02914-9] [Reference Citation Analysis]
4 Hovaguimian A, Roth J. Management of chronic migraine. BMJ 2022;379:e067670. [PMID: 36216384 DOI: 10.1136/bmj-2021-067670] [Reference Citation Analysis]
5 Saçmacı H, Tanik N, İnan LE. Current Perspectives on the Impact of Chronic Migraine on Sleep Quality: A Literature Review. Nat Sci Sleep 2022;14:1783-800. [PMID: 36225323 DOI: 10.2147/NSS.S335949] [Reference Citation Analysis]
6 Reina-varona Á, Rodríguez de Rivera-romero B, Cabrera-lópez CD, Fierro-marrero J, Sánchez-ruiz I, La Touche R. Exercise interventions in migraine patients: a YouTube content analysis study based on grades of recommendation. PeerJ 2022;10:e14150. [DOI: 10.7717/peerj.14150] [Reference Citation Analysis]
7 Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F. Gepants - a long way to cure: a narrative review. Neurol Sci 2022;43:5697-708. [PMID: 35650458 DOI: 10.1007/s10072-022-06184-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Duan S, Ren Z, Xia H, Wang Z, Zheng T, Liu Z. Association between sleep quality, migraine and migraine burden. Front Neurol 2022;13:955298. [DOI: 10.3389/fneur.2022.955298] [Reference Citation Analysis]
9 Rosignoli C, Ornello R, Onofri A, Caponnetto V, Grazzi L, Raggi A, Leonardi M, Sacco S. Applying a biopsychosocial model to migraine: rationale and clinical implications. J Headache Pain 2022;23:100. [PMID: 35953769 DOI: 10.1186/s10194-022-01471-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cao W, Shen Y, Zhong J, Chen Z, Wang N, Yang J. The Patent Foramen Ovale and Migraine: Associated Mechanisms and Perspectives from MRI Evidence. Brain Sciences 2022;12:941. [DOI: 10.3390/brainsci12070941] [Reference Citation Analysis]
11 Steiner TJ, Terwindt GM, Katsarava Z, Pozo-rosich P, Gantenbein AR, Roche SL, Dell’agnello G, Tassorelli C. Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process. Cephalalgia. [DOI: 10.1177/03331024221110102] [Reference Citation Analysis]
12 Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Schiano Di Cola F, d'Onofrio F, Finocchi C, Bertuzzo D, Bono F, Ranieri A, Albanese M, Messina R, Doretti A, Di Piero V, Cevoli S, Barbanti P, Vernieri F; GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol 2022. [PMID: 35763113 DOI: 10.1007/s00415-022-11226-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Couch JR, Stewart KE. Persistence of headache and its relation to other major sequelae following traumatic brain injury at 2–8 years after deployment‐related traumatic brain injury in veterans of Afghanistan and Iraq wars. Headache 2022;62:700-717. [DOI: 10.1111/head.14303] [Reference Citation Analysis]
14 Davis L, Torphy B. Managing migraine on the frontline: Identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care. British Journal of Pain. [DOI: 10.1177/20494637221104292] [Reference Citation Analysis]
15 Aladdin YS, Alsharif R, Mattar W, Alturki M, Malli IA, Alghamdi Y, Ismail A, Shirah B. Migraine Prevalence and Analysis of Dietary Habits in Relation to Headache in the Female Population: A Single-Center Study From Jeddah, Saudi Arabia. Cureus. [DOI: 10.7759/cureus.24848] [Reference Citation Analysis]
16 Yesantharao PS, Lee E, Klifto KM, Colakoglu S, Dellon AL, Reddy SK. A Markov Analysis of Surgical versus Medical Management of Chronic Migraines. Plast Reconstr Surg 2022;149:1187-96. [PMID: 35311748 DOI: 10.1097/PRS.0000000000009048] [Reference Citation Analysis]
17 Kubota GT. It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine. Arq Neuro-Psiquiatr 2022;80:218-226. [DOI: 10.1590/0004-282x-anp-2022-s112] [Reference Citation Analysis]
18 Kalantar Hormozi B, Tavoli A, Abdollahi A. Perceived Parental Styles and Alexithymia in Adult Iranian Migraine Patients: The Mediating Role of Emotional Schemas. J Genet Psychol 2022;:1-13. [PMID: 35356843 DOI: 10.1080/00221325.2022.2051421] [Reference Citation Analysis]
19 McAllister P, Kudrow D, Cady R, Hirman J, Ettrup A. Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia 2022;:3331024221089567. [PMID: 35332807 DOI: 10.1177/03331024221089567] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Groth M, Katsarava Z, Ehrlich M. Results of the gErman migraine PatIent Survey on medical Care and prOPhylactic treatment Experience (EPISCOPE). Sci Rep 2022;12:4589. [PMID: 35301435 DOI: 10.1038/s41598-022-08716-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Mcallister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. J Headache Pain 2022;23. [DOI: 10.1186/s10194-021-01376-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Front Neurol 2021;12:788159. [PMID: 35069416 DOI: 10.3389/fneur.2021.788159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Johnston K, Harris L, Powell L, Popoff E, Coric V, L'Italien G, Schreiber CP. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J Headache Pain 2022;23:10. [PMID: 35038983 DOI: 10.1186/s10194-021-01378-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 van der Vaart J, Merki-feld GS. Sex hormone-related polymorphisms in endometriosis and migraine: A narrative review. Womens Health (Lond Engl) 2022;18:174550572211113. [DOI: 10.1177/17455057221111315] [Reference Citation Analysis]
25 Martelletti P. Public Health. Migraine in Medicine 2022. [DOI: 10.1007/978-3-030-97359-9_1] [Reference Citation Analysis]
26 Goetz A, McCormick S, Phillips R, Friedman D. CE: Diagnosing and Managing Migraine. Am J Nurs 2022;122:32-43. [PMID: 34882585 DOI: 10.1097/01.NAJ.0000805640.82646.ac] [Reference Citation Analysis]
27 Digre KB, Friedman DI. Headache and Eye Pain. Albert and Jakobiec's Principles and Practice of Ophthalmology 2022. [DOI: 10.1007/978-3-030-42634-7_49] [Reference Citation Analysis]
28 Gottschalk C, Basu A, Blumenfeld A, Torphy B, Marmura MJ, Pavlovic JM, Dumas PK, Lalvani N, Buse DC. The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 2022;5:251581632211345. [DOI: 10.1177/25158163221134593] [Reference Citation Analysis]
29 Thiele A, Klehr L, Strauß S, Angermaier A, Schminke U, Kronenbuerger M, Naegel S, Fleischmann R. Preventive treatment with CGRP monoclonal antibodies restores brain stem habituation deficits and excitability to painful stimuli in migraine: results from a prospective case-control study. J Headache Pain 2021;22:149. [PMID: 34895133 DOI: 10.1186/s10194-021-01364-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Papakonstantinou D, Tomos C. Workplace productivity loss as a result of absenteeism and presenteeism in chronic and episodic migraine: a scoping review. IJWHM 2021;15:38-53. [DOI: 10.1108/ijwhm-05-2021-0123] [Reference Citation Analysis]
31 Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 2021. [PMID: 34826192 DOI: 10.1111/ene.15197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
32 Boinpally R, Lu K. Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium. Clin Pharmacol Drug Dev 2021. [PMID: 34811955 DOI: 10.1002/cpdd.1034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Riggins N, Ehrlich A. The Use of Behavioral Modalities for Headache During Pregnancy and Breastfeeding. Curr Pain Headache Rep 2021;25:66. [PMID: 34668111 DOI: 10.1007/s11916-021-00980-1] [Reference Citation Analysis]
34 Kim BK, Cho SJ, Kim CS, Sakai F, Dodick DW, Chu MK. Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea. J Clin Neurol 2021;17:546-57. [PMID: 34595863 DOI: 10.3988/jcn.2021.17.4.546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Latysheva NV, Filatova EG, Berdnikova AV. Expanding the possibilities of migraine attack relief: effcacy and safety of zolmitriptan and patient reports. Medicinskij alfavit 2021. [DOI: 10.33667/2078-5631-2021-22-31-36] [Reference Citation Analysis]
36 Kiryanova EA, Kovalchuk NA, Tabeeva GR. Results of migraine treatment depending on its menstrual association. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-12-426-432] [Reference Citation Analysis]
37 Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia 2021;:3331024211042385. [PMID: 34521260 DOI: 10.1177/03331024211042385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
38 Gil-Gouveia R, Miranda R. Indirect costs attributed to headache: A nation-wide survey of an active working population. Cephalalgia 2021;:3331024211043795. [PMID: 34521261 DOI: 10.1177/03331024211043795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Kollewe K, Gaul C, Gendolla A, Sommer K. Lebensqualität steigt, Inanspruchnahme von Gesundheitsleistungen sinkt. Schmerzmed 2021;37:50-55. [DOI: 10.1007/s00940-021-3195-1] [Reference Citation Analysis]
40 Kiryanova EA, Tabeeva GR. Menstrual cycle and gynecologic pathology in menstrual-related migraine. RJTAO 2021;13:12-17. [DOI: 10.14412/2074-2711-2021-4-12-17] [Reference Citation Analysis]
41 Demarquay G, Moisset X, Lantéri-Minet M, de Gaalon S, Donnet A, Giraud P, Guégan-Massardier E, Lucas C, Mawet J, Roos C, Valade D, Ducros A. Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 1: Diagnosis and assessment. Rev Neurol (Paris) 2021:S0035-3787(21)00612-3. [PMID: 34340812 DOI: 10.1016/j.neurol.2021.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Boudreau G, Finkelstein I, Graboski C, Ong M, Christie S, Sommer K, Bhogal M, Davidovic G, Becker WJ. OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. Can J Neurol Sci 2021;:1-13. [PMID: 34218836 DOI: 10.1017/cjn.2021.153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L'Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2021;:1-12. [PMID: 34148501 DOI: 10.1080/14737167.2021.1945444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
44 Thiele A, Strauß S, Angermaier A, Klehr L, Bartsch L, Kronenbuerger M, Schmidt S, Fleischmann R. Treatment Realities of Headache Disorders in Rural Germany by the Example of the Region of Western Pomerania. Brain Sci 2021;11:839. [PMID: 34202861 DOI: 10.3390/brainsci11070839] [Reference Citation Analysis]
45 Estave PM, Beeghly S, Anderson R, Margol C, Shakir M, George G, Berger A, O'Connell N, Burch R, Haas N, Powers SW, Seng E, Buse DC, Lipton RB, Wells RE. Learning the full impact of migraine through patient voices: A qualitative study. Headache 2021;61:1004-20. [PMID: 34081779 DOI: 10.1111/head.14151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
46 Kollewe K, Gaul C, Gendolla A, Sommer K. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. J Headache Pain 2021;22:50. [PMID: 34078259 DOI: 10.1186/s10194-021-01260-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Kim BK, Chu MK, Yu SJ, Dell'Agnello G, Han JH, Cho SJ. Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain 2021;22:45. [PMID: 34030630 DOI: 10.1186/s10194-021-01250-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
48 Boinpally R, McNamee B, Yao L, Butler M, McGeeney D, Borbridge L, Periclou A. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial. Clin Pharmacol Drug Dev 2021;10:1099-107. [PMID: 33942560 DOI: 10.1002/cpdd.940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
49 Schwedt TJ, Sahai-Srivastava S, Murinova N, Birlea M, Ahmed Z, Digre K, Lopez K, Mullally W, Blaya MT, Pippitt K, Cutrer FM, DeLange J, Schecht H, Rizzoli P, Lane J, Wald J, Cortez MM, Martin VT, Spare NM, Hentz JG, Robert T, Dodick DW; MOTS Investigators. Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial. Cephalalgia 2021;41:1053-64. [PMID: 33938249 DOI: 10.1177/03331024211006903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 García-Azorín D, Abelaira-Freire J, Rodriguez-Adrada E, González-García N, Planchuelo-Gómez Á, Guerrero ÁL, Porta-Etessam J, Martín-Sánchez FJ. Temporal distribution of emergency room visits in patients with migraine and other headaches. Expert Rev Neurother 2021;21:599-605. [PMID: 33749486 DOI: 10.1080/14737175.2021.1906222] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Buse DC, Armand CE, Charleston L 4th, Reed ML, Fanning KM, Adams AM, Lipton RB. Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. Headache 2021;61:628-41. [PMID: 33797078 DOI: 10.1111/head.14103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
52 Donnet A, Ducros A, Radat F, Allaf B, Chouette I, Lanteri-Minet M. Severe migraine and its control: A proposal for definitions and consequences for care. Rev Neurol (Paris) 2021:S0035-3787(21)00457-4. [PMID: 33810839 DOI: 10.1016/j.neurol.2020.11.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB. Migraine: epidemiology and systems of care. Lancet 2021;397:1485-95. [PMID: 33773613 DOI: 10.1016/S0140-6736(20)32160-7] [Cited by in Crossref: 100] [Cited by in F6Publishing: 110] [Article Influence: 100.0] [Reference Citation Analysis]
54 Guerrero AL, Negro A, Ryvlin P, Skorobogatykh K, Sanchez-De La Rosa R, Israel-Willner H, Sundal C, MacGregor EA. Need of guidance in disabling and chronic migraine identification in the primary care setting, results from the european MyLife anamnesis survey. BMC Fam Pract 2021;22:54. [PMID: 33743604 DOI: 10.1186/s12875-021-01402-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kim KM, Cho SJ, Shin HJ, Yang KI, Kim D, Yun CH, Chu MK. Prevalence, Disability, and Management Patterns of Migraine in Korea: Nationwide Survey Data from 2009 and 2018. J Clin Neurol 2021;17:77-85. [PMID: 33480202 DOI: 10.3988/jcn.2021.17.1.77] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
56 Min KC, Kraft WK, Bondiskey P, Colón-González F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Clin Transl Sci 2021;14:599-605. [PMID: 33142014 DOI: 10.1111/cts.12917] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
57 Tzeng HR, Lee MT, Fan PC, Knutson DE, Lai TH, Sieghart W, Cook J, Chiou LC. α6GABAA Receptor Positive Modulators Alleviate Migraine-like Grimaces in Mice via Compensating GABAergic Deficits in Trigeminal Ganglia. Neurotherapeutics 2021;18:569-85. [PMID: 33111258 DOI: 10.1007/s13311-020-00951-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
58 Dodick DW, Shewale AS, Lipton RB, Baum SJ, Marcus SC, Silberstein SD, Pavlovic JM, Bennett NL, Young WB, Viswanathan HN, Doshi JA, Weintraub H. Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data. J Prim Care Community Health 2020;11:2150132720963680. [PMID: 33095099 DOI: 10.1177/2150132720963680] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
59 Al-Hassany L, Haas J, Piccininni M, Kurth T, Maassen Van Den Brink A, Rohmann JL. Giving Researchers a Headache - Sex and Gender Differences in Migraine. Front Neurol 2020;11:549038. [PMID: 33192977 DOI: 10.3389/fneur.2020.549038] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
60 Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB. Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache: The Journal of Head and Face Pain 2020;60:2340-56. [DOI: 10.1111/head.13966] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
61 Ishii R, Schwedt TJ, Kim S, Dumkrieger G, Chong CD, Dodick DW. Effect of Migraine on Pregnancy Planning: Insights From the American Registry for Migraine Research. Mayo Clinic Proceedings 2020;95:2079-89. [DOI: 10.1016/j.mayocp.2020.06.053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
62 Quintas M, Neto JL, Sequeiros J, Sousa A, Pereira-Monteiro J, Lemos C, Alonso I. Going Deep into Synaptic Vesicle Machinery Genes and Migraine Susceptibility - A Case-Control Association Study. Headache 2020;60:2152-65. [PMID: 32979221 DOI: 10.1111/head.13957] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Donisi V, Mazzi MA, Gandolfi M, Deledda G, Marchioretto F, Battista S, Poli S, Giansante M, Geccherle E, Perlini C, Smania N, Del Piccolo L. Exploring Emotional Distress, Psychological Traits and Attitudes in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylaxis versus Withdrawal Treatment. Toxins (Basel) 2020;12:E577. [PMID: 32911799 DOI: 10.3390/toxins12090577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
64 Cape S. Access to Migraine Treatments in Ontario, Canada: A Review of the Ontario Drug Benefit Program. Headache 2020;60:1888-900. [PMID: 32757445 DOI: 10.1111/head.13918] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Bonfert MV, Börner C, Gerstl L, Hannibal I, Mathonia N, Huß K, Rahmsdorf B, Kainz C, Klose B, Koenig H, Urban G, Schandelmaier P, Renner T, Albers L, Krieg SM, Sollmann N, Heinen F, Landgraf MN. [Migraine in childhood and adolescence-neurostimulation as a future innovative approach in terms of a multimodal treatment regimen]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:872-80. [PMID: 32504242 DOI: 10.1007/s00103-020-03169-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, Tessitore A, Tedeschi G. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 2020;21:69. [PMID: 32517693 DOI: 10.1186/s10194-020-01143-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 28.0] [Reference Citation Analysis]
67 Renner T, Sollmann N, Heinen F, Albers L, Trepte-Freisleder F, Klose B, König H, Krieg SM, Bonfert MV, Landgraf MN. Alleviation of migraine symptoms by application of repetitive peripheral magnetic stimulation to myofascial trigger points of neck and shoulder muscles - A randomized trial. Sci Rep 2020;10:5954. [PMID: 32249788 DOI: 10.1038/s41598-020-62701-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
68 Ranoux D. Toxine botulique de type A et migraine chronique : une revue des données récentes. Bulletin de l'Académie Nationale de Médecine 2020;204:386-392. [DOI: 10.1016/j.banm.2020.01.020] [Reference Citation Analysis]
69 Adewuyi EO, Sapkota Y, International Endogene Consortium Iec, andMe Research Team, International Headache Genetics Consortium Ihgc, Auta A, Yoshihara K, Nyegaard M, Griffiths LR, Montgomery GW, Chasman DI, Nyholt DR. Shared Molecular Genetic Mechanisms Underlie Endometriosis and Migraine Comorbidity. Genes (Basel) 2020;11:E268. [PMID: 32121467 DOI: 10.3390/genes11030268] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
70 Kiryanova EA, Tabeeva GR. Features of comorbidity of menstrual-related migraine. RJTAO 2020;12:76-80. [DOI: 10.14412/2074-2711-2020-1-76-80] [Reference Citation Analysis]
71 Wells RE, Seng EK, Edwards RR, Victorson DE, Pierce CR, Rosenberg L, Napadow V, Schuman-Olivier Z. Mindfulness in migraine: A narrative review. Expert Rev Neurother 2020;20:207-25. [PMID: 31933391 DOI: 10.1080/14737175.2020.1715212] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
72 Ankrom W, Bondiskey P, Li CC, Palcza J, Liu W, Dockendorf MF, Matthews C, Panebianco D, Reynders T, Wagner JA, Jakate A, Mesens S, Kraft WK, Marcantonio EE. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. Clin Transl Sci 2020;13:462-72. [PMID: 31899602 DOI: 10.1111/cts.12728] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
73 He YD, Yan XL, Qin C, Zhang P, Guo ZN, Yang Y. Transcatheter Patent Foramen Ovale Closure Is Effective in Alleviating Migraine in a 5-Year Follow-Up. Front Neurol 2019;10:1224. [PMID: 31803135 DOI: 10.3389/fneur.2019.01224] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]